INTRODUCTION
Infectious diseases are a significant cause of morbidity and mortality, accounting for approximately 50 % of all deaths in tropical countries [1] . Due to indiscriminate use of antibacterial agents in infectious diseases, multidrug resistance in bacteria has become a great challenge to human health [2] . With the increasing prevalence of multi-drug resistant bacteria, appearances of strains with reduced susceptibility to antibiotics and their inexorable invasion of hospitals and communities, there are increases in health care costs [3] , many untreatable bacterial infections and the need to search for new infection-fighting strategies and novel antibacterial agents [4] .
The use of antimicrobial combinations to achieve synergistic activities against targeted microorganisms is a potential strategy for overcoming bacterial resistance [5] . Theoretically, it is aimed at broadening antimicrobial empirical coverage, improving efficacy against isolates with a minimum inhibitory concentration (MIC) at or approaching the breakpoint for susceptibility as well as preventing the further emergence of resistant organisms [6] . While preventing the emergence of reduced susceptibility, it achieves bactericidal synergy and provides activity against stationaryphase organisms and organisms growing in biofilm. The use of drug combinations is an excellent strategy to avoid drug resistance since different drug target sites are attacked simultaneously. Although previous studies indicated interactions between other aminoglycosides or nitroimidazole (metronidazole) and other antibacterial agents [7, 8] , combining kanamycin and metronidazole against bacteria of clinical importance has not been reported. This study, therefore, aimed at assessing the effect of combining kanamycin and metronidazole, having different mechanisms of action, against bacteria of clinical relevance.
EXPERIMENTAL

Bacterial strain
The bacteria used in this study include [9] .
Antibiotic susceptibility testing
Each of the bacterial isolates was standardized using colony suspension method [10] . Each strain's suspension was matched with 0.5
McFarland standards to give a resultant concentration of 1 × 10 6 cfu/ml. The antibiotic susceptibility testing was determined by swabbing the Mueller-Hinton agar (MHA) (Oxoids U.K) plates with the resultant saline suspension of each bacterial strain. Wells were then bored into the agar medium with heat sterilized 6 mm cork borer. The wells were filled with 100 µl of different concentrations (62.5, 125 and 250 µg/ml) of each of the antibiotics without allowing spillage of the solutions onto the agar surfaces. To determine the combinatorial effect of the antibiotics, different solutions containing combined concentrations (62.5, 125 and 250 µg/ml) of kanamycin and metronidazole were used. The plates were allowed to stand for at least 30 min before being incubated at 37 °C for 24 h. The determinations were done in duplicate. After 24 h of incubation, the plates were examined for inhibition zones. The diameter of the inhibition zones produced by the respective antibiotic alone and their combinations were measured and interpreted using the CLSI zone diameter interpretative standards [11] .
Determination of minimum inhibitory concentration (MIC)
The minimum inhibitory concentrations (MICs) for the two antibiotics were determined in duplicate by the macrobroth dilution method in Mueller Hinton broth. To determine the MICs of each antibiotic, different concentrations of each of the antibiotics (0.0019 -500) μg/ml were prepared by serial dilution in Mueller Hinton broth. To determine their combined effects, combinations of different concentrations were used in the determination of the MICs of each of the antibiotics were used. The tubes were inoculated with 100 µl of each of the adjusted bacterial strains before incubating at 37 o C for 24 h. Blank Mueller Hinton broth was used as negative control. The MICs were determined in duplicates. The MIC was defined as the lowest concentrations that showed no growth in the Mueller Hinton broth.
Checkerboard assay
The interactions between the two antibiotics were determined using the checkerboard as previously described [12] . The range of drug concentration used in this assay encompassed the MIC for each antibiotic used in the analysis. The fractional inhibitory concentration (FIC) was derived from the lowest concentrations of the two antibiotics in combination permitting no visible growth of the test organisms in the Mueller Hinton broth after incubation for 24 h at 37 o C. FIC indices were calculated using the formula, FIC index = (MIC of kanamycin in combination/MIC of kanamycin alone) + (MIC of metronidazole in combination/MIC of metronidazole alone). In this study, synergy was defined as ∑FIC ≤ 0.5, additivity as 0.5 < ∑FIC ≤ 1, indifference as 1 < ∑FIC ≤ 4. Concentrations within the FIC panel were such that the MIC of each antibiotic was in the middle of the range of concentrations tested but lower than the MICs of the respective antibiotics.
Determination of rate of kill
The rates of kill by the combined antibiotics were carried out using a modified plating technique of Eliopoulos and Moellering [13] . The combined antibiotics incorporated into 10 ml of Mueller Hinton broth in McCartney bottles at ½ MIC and MIC were inoculated with approximately 1010 cfu/ml further verified by total viable count. Inoculated Mueller Hinton broth without combined antibiotics and uninoculated Mueller Hinton broth incorporated with the combined antibiotics at the test concentrations were included as controls. The tubes were incubated at 37 o C on an orbital shaker at 120 rpm. A 100 µl aliquot was removed from the culture medium at 0, 24 and 48 h for the determination of cfu/ml by plating out 25 µl of each of the dilutions in duplicates. After incubating at 37 o C for 24 h, emergent bacterial colonies were counted, cfu/ml calculated and compared with the counts obtained with antibiotic-free cultures, used as control.
Statistical analysis
Data, analyzed by SPSS V.16 (Statistical Program for Social Sciences, SPSS Corporation, Chicago, IL), were expressed as means ± standard deviations (SD) of duplicate determinations. One way analysis of variance (ANOVA) and the Duncan's New Multiple-range test were used to determine the differences among the means. P < 0.05 was regarded as significant. On combining different concentrations of the two antibiotics, concentration dependent significant synergistic interactions were observed. The resultant zones of inhibition from the antibacterial combinations were wider than those obtained from the antibacterial activities of each of the antibiotics (Table 1) . Though the bacteria showed varied resistance to both antibiotics, resistant colonies were not isolated within the zones of inhibition and fuzzy zones were not found around the edges of the zones of inhibition.
RESULTS
Acinetobacter
From the macrobroth assay, the test isolates were highly resistant to the two antibiotics by exhibiting minimum inhibitory concentrations (MICs) ranging between 15.625 and >250 µg/ml for kanamycin and 15.625 -125 µg/ml for metronidazole. On combining the two antibiotics against these bacteria, the MICs of both antibiotics were drastically reduced in the range between ½ MIC and 1/8 MIC with a simultaneous increase in the antibacterial activity of the combined antibiotics ( Table 2 ). The results of both assays were complementary. The significant reduction in the MICs and the observed increase in the inhibition zones from the combined antibiotics showed that the resultant effect of combining these two antibiotics was synergy.
In the checkerboard assay, antibacterial combinations showed synergistic interaction against most of the bacteria except Acinetobacter calcoaceuticus UP, Enterobacter claoacae ATCC 13047 and Shigella flexneri KZN. While the fractional inhibitory concentration indices (FICIs) showed synergy ranging from 0.3125 -0.5, an additive interaction was indicated with FICI ranging between 0.5313 and 1.25 and no antagonism was recorded from the antibacterial combinations.
The time-kill assay results presented as changes in the log 10 cfu/ml of viable colonies showed that the antibacterial combinations exhibited a significant bactericidal activity. The bactericidal activity was defined as being equal to 3 log 10 cfu/ml or greater reduction in the viable colony count relative to the initial inoculum [14] . Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 29212, Bacillus cereus ATCC 10702, Enterobacter cloacae ATCC 13047 and Micrococcus luteus were completely annihilated by the combination of kanamycin and (Table 3) . A post-antibiotic treatment bioassay done after 48 h showed that all isolates not totally inhibited within 24 h incubation period had an increase in cfu/ml.
DISCUSSION
Due to the frequent development of resistance during monotherapy treatment of infected patients, multiple combinations of antibacterial agents are being proposed [15] . These were to effectively treat mixed and severe infections, enhance antibacterial activity, reduce the time needed for long-term antimicrobial therapy and prevent the emergence of resistant microorganisms [16] because drug combinations are characterized by an increased activity and tolerability compared to that of monotherapy and those used to increase the killing of single-drug resistant strains or mutants.
In this study, the checkerboard method demonstrated synergy between kanamycin and metronidazole for the majority of the strains while antagonism was not observed. The combined antibiotics indicated ability to improve the bactericidal effects of each other on both Gramnegative and Gram-positive bacteria. This is in agreement with previous reports on interaction between aminoglycosides and other antibacterial agents [17] . Their combination in chemotherapy could decrease resistance development, broaden antibacterial spectrum and encourage synergistic antibacterial activity [18] .
As determined by Eliopoulos and Moellering [13], antibiotic combinations that reduced the original inocula by ≥ 2 log 10 cfu/ml were considered synergy while antagonism is a < 2 log 10 change in cfu/ml when compared with the activity of the individual antibiotic after 24 h incubation period. The time-kill assay confirmed the synergy between kanamycin and metronidazole as indicated by the checkerboard assay. This synergy that resulted in enhanced antibacterial effects from antibiotics having different mechanisms of action could have resulted from the formation of a complex compound with enhanced antibacterial activity. Since kanamycin prevents bacteria from synthesizing proteins by binding to 16S rRNA of 30S subunit and metronidazole is reduced to cytotoxic polar compounds able to cause DNA strand breakage, DNA helix and nucleic acid destabilization in bacteria [19] , the synergy of the antibacterial combination could be a means of achieving effective therapy at a reduced cost with a drastic reduction or loss of vestibular and auditory toxicity often associated with the aminoglycosides While the lack of antagonism between the antibiotics suggested that kanamycin or metronidazole may be effective in monotherapy and combination therapy, this synergy will reduce the dose of each drug in the [20] .
Although bactericidal drugs prevent the emergence of resistant mutants by killing the microorganism [21] while synergy and bactericidal therapy could be achieved as long as the organism does not exhibit high-level resistance to aminoglycoside [22] , it is evident, from this study, the highly resistant bacteria with MIC ranging between 15.625 and >250 µg/ml for kanamycin were killed by its combination with metronidazole to which the MICs were between 15.625 and 125 µg/mL for the different isolates. 
CONCLUSION
Combining existing antimicrobial agents such as kanamycin and metronidazole can improve delivery of safe and cost effective patient care in an era where research into discovery of new agents is limited and expensive. In clinical settings, this study emphasizes the potential beneficial value of combining kanamycin and metronidazole for treating seriously ill patients with infections caused by the pathogens tested, especially in the absence of other therapeutic options. Future studies in in vivo infection models would provide a better understanding of the therapeutic potential and safety of kanamycinmetronidazole combinations.
